TerminatedPhase 2NCT04428775

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AZTherapies, Inc.
Principal Investigator
David R. Elmaleh, PhD
AZTherapies, Inc.
Intervention
ALZT-OP1a (cromolyn)(drug)
Enrollment
12 enrolled
Eligibility
18-75 years · All sexes
Timeline
20202021

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04428775 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials